CTX310 CRISPR therapy reduces LDL cholesterol at one year
A phase 1 trial published in the New England Journal of Medicine shows that a single intravenous infusion of the CRISPR-Cas9 therapy CTX310 reduced bad LDL cholesterol by 52.5% and … Read More